Medical

UK-based Synairgen has announced positive data from a Phase 2 trial of its SNG001 inhaled interferon beta as protection against the common cold and other respiratory viral infections in asthma patients. According to the company, SNG001 showed statistically significant improvements compared to placebo in prevention of symptom worsening during the first week of … [Read more...] about Synairgen announces positive Phase 2 results for inhaled interferon beta

Shin Nippon Biomedical Laboratories has announced results from a Phase 1 study of its intranasal zolmitriptan formulation (TRZ) for the treatment of migraine headaches. The company is developing several intranasal drugs based on its μco muco-adhesive powder carrier system and intranasal powder delivery device. According to SNBL, the study, which compared three … [Read more...] about Positive Phase 1 results for dry powder intranasal zolmitriptan

According to Pearl Therapeutics, the company has produced metered dose inhalers (MDI) with the ability to deliver a 300ng dose of glycopyrrolate (GP) per actuation. Pearl formulated the GP for the nanogram-dose inhalers using the company's porous particle cosuspension technology and has initiated a Phase 2b study to evaluate safety and efficacy of twice a day dosing … [Read more...] about Pearl Therapeutics creates nanogram-dose MDIs

Three Phase 3 studies of Novartis's QVA149 indacaterol /glycopyrronium bromide dry powder inhaler for the treatment of COPD have met their primary endpoints according to the company. The SHINE study demonstrated superiority in trough FEV1 for QVA 149 compared to indacaterol alone, glycopyrronium alone, tiotropium, and placebo in more than 2,000 patients with moderate … [Read more...] about QVA 149 Phase 3 studies meet primary endpoints

Almirall has published full results from the ATTAIN (Aclidinium To Treat Airway obstruction In COPD patieNts) study in The European Respiratory Journal (ERJ). ATTAIN was a six-month double-blind placebo-controlled study that compared two doses of inhaled aclidinium (200μg and 400μg twice daily) to placebo in patients with COPD. According to the company the 400 µg dose … [Read more...] about Almirall publishes full results from aclidinium bromide study

A £3.1 million grant from the UK National Institute for Health Research (NIHR) and the Medical Research Council (MRC) will fund a gene therapy study in which 130 children and adults with cystic fibrosis will receive either an inhaled placebo or inhaled DNA delivered using lipids. The UK Cystic Fibrosis Gene Therapy Consortium (GTC) is coordinating the trial. The GTC … [Read more...] about Inhaled gene therapy for CF study gets funding

Teva Pharmaceutical has announced positive results from four Phase 3 clinical studies of QNASL beclomethasone dipropionate HFA nasal aerosol for the treatment of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). Previously released data demonstrated that treatment with QNASL improved nasal symptom scores over the first 30 weeks of a 52-week … [Read more...] about Teva announces positive Phase 3 results for QNASL dry nasal aerosol

Meda has announced positive results from three studies of its Dymista azelastine hydrochloride/fluticasone propionate nasal spray for the treatment of seasonal allergic rhinitis. The company filed both an NDA for the product, currently known as MP29-02, and an MAA in 2011. One long-term study showed that the product is well tolerated, with fewer than 3% of patients … [Read more...] about Positive Phase 3 results for Meda’s Dymista nasal spray

To celebrate its 200th anniversary, the New England Journal of Medicine (NEJM) is publishing a series of special articles reviewing progress in medicine since 1812. As part of the series, an article in the March 1, 2012 issue titled "A Patient with Asthma Seeks Medical Advice in 1828, 1928, and 2012" presents a fictionalized series of doctor's notes on the treatment … [Read more...] about NEJM: 200 years of asthma treatment